GlassScriptPhysician profile
Sima Hodavance
NPI 1982921375
$45,130.80
in general payments reported to CMS, 2019-2025
15 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $47.97 · 2021: $272 · 2022: $12K · 2023: $20K · 2024: $12K · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $2,752 · Travel and Lodging: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,310.00 |
| Food and Beverage | $2,751.97 |
| Travel and Lodging | $1,868.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35,908.11 | 2022-2024 | Jardiance |
| Abbott Laboratories | $4,942.63 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $3,750.20 | 2022-2024 | Jardiance |
| Abiomed | $139.76 | 2023-2024 | Impella |
| Boston Scientific Corporation | $118.08 | 2019 | |
| Impulse Dynamics (USA) INC. | $93.28 | 2024 | Optimizer |
| Novartis Pharmaceuticals Corporation | $35.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.32 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.89 | 2019 | |
| Philips North America LLC | $24.95 | 2025 | Holter |
| Chiesi USA, INC. | $16.95 | 2019 | |
| Novo Nordisk INC | $16.25 | 2019 | |
| Medtronic Vascular, INC. | $14.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sima Hodavance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.